BIOFRONTERA AG/ADR (NASDAQ:BFRA) has been assigned a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy recommendation.

Brokerages have set a 12 month consensus price objective of $21.75 for the company, according to Zacks. Zacks has also assigned BIOFRONTERA AG/ADR an industry rank of 48 out of 256 based on the ratings given to related companies.

Separately, Lake Street Capital dropped their price objective on shares of BIOFRONTERA AG/ADR from $24.00 to $21.00 and set a “buy” rating on the stock in a report on Wednesday, July 10th.

NASDAQ BFRA remained flat at $$15.35 on Monday. 62 shares of the company’s stock traded hands, compared to its average volume of 405. The stock has a 50-day moving average of $16.81. The company has a quick ratio of 3.38, a current ratio of 3.84 and a debt-to-equity ratio of 1.56. BIOFRONTERA AG/ADR has a fifty-two week low of $11.04 and a fifty-two week high of $18.32.

BIOFRONTERA AG/ADR (NASDAQ:BFRA) last released its quarterly earnings results on Wednesday, May 29th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.17) by $0.03. BIOFRONTERA AG/ADR had a negative net margin of 62.81% and a negative return on equity of 95.81%. The business had revenue of $7.73 million for the quarter.


Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that result in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of actinic keratosis.

See Also: Diversification in Investing

Get a free copy of the Zacks research report on BIOFRONTERA AG/ADR (BFRA)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for BIOFRONTERA AG/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOFRONTERA AG/ADR and related companies with's FREE daily email newsletter.